October 27, 2020 | News
Surrey Research Park tenant, ANGLE, a liquid biopsy company that develops products for use in rare cell diagnostics, has raised gross proceeds of £20m through a conditional placing on the London Stock Exchange.
ANGLE focuses on early diagnoses for the prevention, treatment and monitoring of diseases.
The placing comprises 43.4 million shares at a price of 46p each.
ANGLE will use the funding for its metastatic breast cancer and ovarian cancer products, establishing clinical laboratories for pharma services, assay development and commercial expansion.